The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients. - Wikidata - awgldk - TriplyDB

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.

http://www.wikidata.org/entity/Q39222469

about

BACE1 across species: a comparison of the in vivo consequences of BACE1 deletion in mice and rats Drug candidates in clinical trials for Alzheimer's disease.Protein misfolding in neurodegenerative diseases: implications and strategies.Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology.BACE inhibition-dependent repair of Alzheimer's pathophysiology.Research update on Alzheimer's disease and introduction to the Expert Review of Neurotherapeutics special issue.Role of BACE1 in Alzheimer's synaptic function.APP mouse models for Alzheimer's disease preclinical studies.BACE1-Dependent Neuregulin-1 Signaling: An Implication for Schizophrenia.The role of histidines in amyloid β fibril assembly.A Translational Systems Pharmacology Model for Aβ Kinetics in Mouse, Monkey, and Human.Fraction n-Butanol of Radix Notoginseng Protects PC12 Cells from Aβ25-35-Induced Cytotoxicity and Alleviates Cognitive Deficits in SAMP8 Mice by Attenuating Oxidative Stress and Aβ Accumulation.The past, present, and future of disease-modifying therapies for Alzheimer's disease.Beta secretase activity in peripheral nerve regeneration.BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer's Disease Pathology.Evaluation of Metabolic and Synaptic Dysfunction Hypotheses of Alzheimer's Disease (AD): A Meta-Analysis of CSF Markers.Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.Effect of sampling on BACE-1 ligands binding free energy predictions via MM-PBSA calculations.Dysregulated Metabolism of the Amyloid-β Protein and Therapeutic Approaches in Alzheimer Disease.Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes.Alzheimer's disease: where next for anti-amyloid therapies?BACE1 inhibition more effectively suppresses initiation than progression of β-amyloid pathology.Nucleic Acid-Based Theranostics for Tackling Alzheimer's Disease.Inhibition of the Aggregation and Toxicity of the Minimal Amyloidogenic Fragment of Tau by Its Pro-Substituted Analogues.Alzheimer disease: BACE1 inhibitor reduces β-amyloid production in humans.Results of Beta Secretase-Inhibitor Clinical Trials Support Amyloid Precursor Protein-Independent Generation of Beta Amyloid in Sporadic Alzheimer's Disease.Computer-Aided Multi-Target Management of Emergent Alzheimer's Disease.Phyto-Therapeutic and Nanomedicinal Approaches to Cure Alzheimer's Disease: Present Status and Future Opportunities Automation vs. Experience: Measuring Alzheimer's Beta-Amyloid 1-42 Peptide in the CSF SMMDB: a web-accessible database for small molecule modulators and their targets involved in neurological diseases Loss of canonical Wnt signaling is involved in the pathogenesis of Alzheimer's disease The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease

P2860

Q30361192-D2E383D8-43B0-4A0B-A9A7-15CE240ECDA5 Q33916749-6FB7C2DA-DA51-4DAD-B99C-FAB615126852 Q37697832-772C8E47-7F07-494D-AAAB-4FB6F87E468C Q38628808-74C3A082-44F5-488E-8C6C-0A40060B4EAF Q38659874-EF04B09F-EE79-48FD-86AF-1FEE8B8DE3CA Q38663691-16C55320-5C66-4DD0-8FAB-5BB0B5F6C911 Q39027024-42904E63-B837-4B44-B267-D1BB6DC39172 Q41555225-A194FE8B-AA55-4487-A19B-105E7FD77A81 Q41582196-B3C3A803-C95D-40CF-AFE5-9D02E395C7CD Q42004797-E0ECDDA7-9878-433C-8D40-DF91FEEB6154 Q42090533-9F44560F-E1D5-42F4-AC7B-D36CFA20BE10 Q42621620-78BD915E-E327-4BAD-996C-B178E9A8F73D Q46102764-79948D84-214B-4058-B811-AE578A868736 Q46244313-2C47D73C-99ED-4156-BCAC-B9C2ACF3128E Q47368687-ABA4C650-D212-4770-9077-C2D16A39EC49 Q47658329-520C95B5-4C55-4F7D-A294-BA2DD3591A07 Q47937645-22E70B60-F00F-4AD0-BC8F-A8E965E6ABE8 Q47940819-02BF165E-84F7-44DA-ADC6-845606314836 Q48022145-36B9C467-6DCF-4A91-BA9C-C6810826308A Q48165579-3EB09D2A-F742-4149-8F10-0E8A74F5E29A Q48169692-F3A783F7-1994-4A8B-9D19-6F9CC5F65C09 Q48231165-0BE3A762-9CBD-4FCF-9655-F8360D241240 Q50074018-788E59F0-347C-473D-BC11-3ACCABB366AE Q50130748-9F7E0E54-EA58-48C6-A2A5-8F429DDA7EBB Q50863156-2A0CEAF1-5A6D-41C6-8A92-6B20AB9A4BDA Q51229646-E41A1F05-31A9-4304-8E05-BF58D9CC65B5 Q55428413-97699220-26AF-4E72-B88B-0695C42153F2 Q55456183-47F5651C-54E2-40BE-B101-2CBFF4601962 Q58571824-F11A10E3-716B-42F1-BCF2-9CDE2CA17A28 Q58719736-4D71FF15-49C0-4AF4-87AB-5746A6CA0465 Q58743091-A9A8FC2B-8203-40A9-9659-749A7C9B843E Q58794829-76C1B311-CB70-46A8-9661-114FD64E6DB1 Q59133137-CC2DE5B5-6485-45E4-BEF8-4795E83353D9

P2860

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients.

http://www.wikidata.org/entity/Q39222469

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The BACE1 inhibitor verubecest ...... Alzheimer's disease patients.

@en

The BACE1 inhibitor verubecestat

@nl

type

label

The BACE1 inhibitor verubecest ...... Alzheimer's disease patients.

@en

The BACE1 inhibitor verubecestat

@nl

prefLabel

The BACE1 inhibitor verubecest ...... Alzheimer's disease patients.

@en

The BACE1 inhibitor verubecestat

@nl

P1433

Q39222469-16ED20E3-6D23-4395-A6FD-7FCC95057E3E

P1476

Q39222469-B6082FD0-5E77-45C2-99FA-A2C64F2593CB

P2093

Q39222469-03AFDA7F-91E9-4332-9BA1-913B4F82341C

Q39222469-0EAE78BE-C2DB-494C-933D-91479196588D

Q39222469-15818AD2-B7F4-4778-89E3-E273FEB99DCE

Q39222469-1C56EADF-D0C4-4694-A3EE-FD9B3598F60F

Q39222469-26C7F878-037D-49F4-9702-B6E6A9BAC2F5

Q39222469-2D4720E6-911D-490D-81CA-199F61A461D5

Q39222469-313C1026-6129-4E5D-A3A5-A55B852270DE

Q39222469-3C733162-1F12-4FFB-AF3B-2D271E0238AC

Q39222469-492DEAFC-F814-4446-BC0F-B3CFF0A4BD20

Q39222469-50359614-A0A4-43E2-8EF0-14266BE5E568

P2860

Q39222469-064D2B55-6612-49B3-BF20-364D3777DC42

Q39222469-0A1376B3-922C-4179-BB21-45C8D211B86A

Q39222469-0FC3FDCB-AD7C-411F-B0B7-50D556169EA3

Q39222469-1339DC83-3371-40C7-B002-B3EA1F8BD0DE

Q39222469-151E2DA4-F46D-4278-9A67-4CF4F8EAFC6A

Q39222469-17D8E9F7-2A2B-4D4B-9E3A-29FF3330E770

Q39222469-1E7E1E33-B7C8-4C57-B519-E522DF9FEFEA

Q39222469-1F7D52C8-9DFB-498A-8D8B-111AE306E5D4

Q39222469-2507EEDB-8C84-4104-BA7F-3E63F7172140

Q39222469-2A125AB6-7957-4605-B2E3-FB2925358D39

P304

Q39222469-51968F10-E64B-402E-B93C-F23B46C10CA8

P31

Q39222469-0DA0FE77-727E-4775-9C80-FEDA5AAEF365

P356

Q39222469-51159605-5A4A-43B6-927A-F3F7A7DCB38B

P407

Q39222469-B96DDF7A-C280-49F1-BF2C-C10284BF56A4

P433

Q39222469-20664D95-8428-4CBB-A57B-9A5657A4DB15

P478

Q39222469-66C0111E-FF0E-444C-ABA1-04F53CA4C15E

P577

Q39222469-7721B681-3E97-49F7-BFE7-C1277CC512AC

P698

Q39222469-E90D907E-B7A4-4CFC-B93F-291239DCA7E8

P921

Q39222469-38065678-216E-4421-97FB-542E0031DF28

P356

SCITRANSLMED.AAD9704

P1433

Science Translational Medicine

P1476

The BACE1 inhibitor verubecest ...... Alzheimer's disease patients.

@en

P2093

Andrew W Stamford

http://www.w3.org/2001/XMLSchema#string

Britta A Mattson

http://www.w3.org/2001/XMLSchema#string

Eric M Parker

http://www.w3.org/2001/XMLSchema#string

Hong Mei

http://www.w3.org/2001/XMLSchema#string

Huub J Kleijn

http://www.w3.org/2001/XMLSchema#string

Jack D Scott

http://www.w3.org/2001/XMLSchema#string

Jack L Tseng

http://www.w3.org/2001/XMLSchema#string

Jared N Cumming

http://www.w3.org/2001/XMLSchema#string

John Palcza

http://www.w3.org/2001/XMLSchema#string

Julie A Stone

http://www.w3.org/2001/XMLSchema#string

P2860

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior

The amyloid hypothesis of Alzheimer's disease at 25 years

Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor That Affords Robust CNS Aβ Reduction

The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans

Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates

Three dimensions of the amyloid hypothesis: time, space and 'wingmen'

Roles of Meltrin beta /ADAM19 in the processing of neuregulin

P304

363ra150

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.AAD9704

http://www.w3.org/2001/XMLSchema#string

P407

P433

363

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27807285

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease